Plasma lipids are associated with white matter microstructural changes and axonal degeneration
Plasma lipids are associated with white matter microstructural changes and axonal degeneration
复制标题
DOI：
10.1007/s11682-020-00311-9
复制
发表时间：
2020-08-03
影响因子：
3.2
通讯作者：
Martinez-Lage, Pablo
中科院分区：
文献类型：
--
作者：
Iriondo, Ane;Garcia-Sebastian, Maite;Martinez-Lage, Pablo
精神错乱是认知障碍的一个危险因素。我们采用扩散张量成像（DTI）研究了273名健康成人的血脂个体差异与白色物质（WM）微结构之间的关系。特别关注7个感兴趣区域（ROI），它们是认知神经回路的结构组成部分。我们还研究了血浆脂质对脑脊液（CSF）神经丝轻链（NfL），轴突变性标志物的影响。低密度脂蛋白（LDL）和甘油三酯（TG）水平与轴向扩散率（AxD）在多个区域呈负相关。高密度脂蛋白（HDL）呈正相关。这种关联与载脂蛋白E（APOE）基因型、血压或他汀类药物的使用无关。LDL调节胼胝体体内NfL与AxD的关系（p = 0.041），右侧扣带回（p = 0.041），在此情况下，右侧穹窿/终纹（p = 0.025）和右侧上级纵束（p = 0.020）中的TG以及右侧下纵束（p = 0.004）和左侧穹窿/终纹（p = 0.001）中的TG。我们的结论是，血脂与WM的微观结构变化和轴突变性，并可能代表从健康老龄化的疾病的过渡的危险因素。
Dislipidemia is a risk factor for cognitive impairment. We studied the association between interindividual variability of plasma lipids and white matter (WM) microstructure, using diffusion tensor imaging (DTI) in 273 healthy adults. Special focus was placed on 7 regions of interest (ROI) which are structural components of cognitive neurocircuitry. We also investigated the effect of plasma lipids on cerebrospinal fluid (CSF) neurofilament light chain (NfL), an axonal degeneration marker. Low density lipoprotein (LDL) and triglyceride (TG) levels showed a negative association with axial diffusivity (AxD) in multiple regions. High density lipoproteins (HDL) showed a positive correlation. The association was independent of Apolipoprotein E (APOE) genotype, blood pressure or use of statins. LDL moderated the relation between NfL and AxD in the body of the corpus callosum (p = 0.041), right cingulum gyrus (p = 0.041), right fornix/stria terminalis (p = 0.025) and right superior longitudinal fasciculus (p = 0.020) and TG in the right inferior longitudinal fasciculus (p = 0.004) and left fornix/stria terminalis (p = 0.001). We conclude that plasma lipids are associated to WM microstructural changes and axonal degeneration and might represent a risk factor in the transition from healthy aging to disease.